This activity is necessary because oncology practice is rapidly evolving, with new evidence and therapies emerging faster that can be consistently integrated into routine care. A gap exists between available clinical trial data and its uniform interpretation and application in the real world setting. This is evident in areas of active controversy such as treatment intensification in mHSPC (metastatic hormone-sensitive prostate cancer), sequencing or CAR T-cell (Chimeric Antigen Receptor T-cell) and bispecific therapies, and management of high-risk hematologic malignancies. As a result, clinicians may differ in treatment selection and sequencing across similar patient scenarios. This activity addresses these gaps by synthesizing current evidence and expert perspectives to support more consistent, evidence-based decision-making.  

Despite rapid advances in oncology, there remains a gap between emerging clinical evidence and its application in routine clinical practice. Significant variability persists in the management of conditions such as mHSPC, high-risk smoldering myeloma, aggressive lymphomas, and sAML (secondary acute myeloid leukemia), particularly regarding treatment intensification and optimal sequencing of therapies. Additionally, uncertainty remains regarding the integration of novel modalities such as CAR-T therapy, bispecific antibodies, and tumor-infiltrating lymphocyte approaches into earlier lines of treatment. Current practice is often influenced by institutional experience and evolving data, leading to inconsistent multidisciplinary decision-making across academic and community settings. Ideal practice would reflect timely, evidence-based, and risk-adapted treatment selection with standardized incorporation of novel therapies and multimodality approaches. This educational activity is designed to address these gaps by clarifying areas of controversy and aligning practice with the most current evidence to improve patient outcomes.